Advertisement

Cardiac arrest from acquired long QT syndrome: A case report

Published:October 28, 2008DOI:https://doi.org/10.1016/j.hrtlng.2008.08.002

      Background

      Many classes of medications initiated by clinicians can cause adverse events, such as cardiac disturbances. One such adverse outcome is that of acquired long QT syndrome, which can lead to arrhythmias and sudden death. When health care practitioners were surveyed about their knowledge of this condition, 20% indicated they knew very little about long QT syndromes and more than 30% failed to check on current therapy before prescribing QT-prolonging medications.

      Methods

      A case will be presented to illustrate the importance of understanding this syndrome.

      Results

      The causes and pathophysiology of acquired long QT syndrome are discussed, and the resources for clinicians to obtain more information and growing number of offending medications leading to acquired long QT syndrome are provided.

      Conclusions

      On-going education is needed to heighten awareness in the health care community to prevent the deleterious outcomes associated with medication induced acquired long QT syndrome.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart & Lung: The Journal of Cardiopulmonary and Acute Care
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mank-Seymour A.R.
        • Richmond J.I.
        • Wood L.S.
        • Reynolds J.M.
        • Fan Y.T.
        • Warnes G.R.
        • et al.
        Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes.
        Am Heart J. 2006; 152: 1116-1122
        • LaPointe N.M.
        • Curtis L.H.
        • Chan K.A.
        • Kramer J.M.
        • Lafata J.E.
        • Gurwitz J.H.
        • et al.
        Frequency of high-risk use of QT-prolonging medications.
        Pharmacoepidemiol Drug Saf. 2006; 15: 361-368
        • Kunkler K.
        Acquired long QT syndrome: risk assessment, prudent prescribing and monitoring, and patient education.
        J Am Acad Nurse Pract. 2002; 14: 382-389
        • Justo D.
        • Zeltser D.
        Torsades de pointes induced by antibiotics.
        Eur J Intern Med. 2006; 17: 254-259
        • Aslam A.F.
        • Aslam A.K.
        • Vasavada N.C.
        • Khan I.A.
        Hypothermia: evaluation, electrocardiographic manifestations, and management.
        Am J Med. 2006; 119: 297-301
        • Al-Khatib S.M.
        • LaPointe N.M.
        • Kramer J.M.
        • Califf R.M.
        What clinicians should know about the QT interval.
        JAMA. 2003; 289: 2120-2127
        • Lankipalli R.S.
        • Zhu T.
        • Guo D.
        • Yan G.-X.
        Mechanisms underlying arrhythmogenesis in long QT syndrome.
        J Electrocardiol. 2005; 38: 69-73
        • Cubeddu L.X.
        QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs.
        Am J Ther. 2003; 106: 452-457
        • Owens R.C.
        QT prolongation with antimicrobial agents.
        Drugs. 2004; 64: 1091-1124
        • Tisdale J.E.
        • Kovacs R.
        • Mi D.
        • MoCabe G.P.
        • Cariera B.L.
        • Sharma N.
        • et al.
        Accuracy of uncorrected versus corrected QT interval for prediction of torsades de pointes associated with intravenous haloperidol.
        Pharmacotherapy. 2007; 27: 175-182
        • Karjalainen J.
        • Viitasalo M.
        • Manttari M.
        • Manninen V.
        Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values.
        J Am Coll Cardiol. 1994; 23: 1547-1553
        • Milne J.R.
        • Ward D.E.
        • Spurrell R.A.
        • Camm A.J.
        The ventricular paced QT interval—the effects of rate and exercise.
        Pacing Clin Electrophysiol. 1982; 5: 352-358
        • Moss A.J.
        • Zareba W.
        • Benhorin J.
        • Coudere J.P.
        • Kennedy H.
        • Locati-Heilbron E.
        • et al.
        ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary.
        Ann Noninvasive Electrocardiol. 2001; 6: 333-341
        • Sommargren C.E.
        • Drew B.J.
        Preventing torsades de pointes by careful cardiac monitoring in hospital settings.
        AACN Adv Crit Care. 2007; 18: 285-293
        • Darpo B.
        • Nebout T.
        • Sager P.T.
        Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use E14 Guideline.
        J Clin Pharmacol. 2006; 46: 498-507
        • Darpo B.
        • Agin M.
        • Kazierad D.J.
        • Layton G.
        • Muirhead G.
        • Gray P.
        • et al.
        Man versus machine: is there an optimal method for QT measurements in thorough QT studies?.
        J Clin Pharmacol. 2006; 46: 598-612
        • Kelly H.G.
        • Fay J.E.
        • Lavery S.G.
        Thioridazine hydrochloride (Mellaril): its effects on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities.
        Can Med Assoc J. 1963; 89: 546-554
        • Curtis L.H.
        • Ostegye T.
        • Sendersky V.
        • Hutchison S.
        • Allen LaPointe N.M.
        • Al-Khatib S.M.
        • et al.
        Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.
        Am J Med. 2003; 114: 135-141
        • Sala M.
        • Vicentini A.
        • Brambilla P.
        • Montomoli C.
        • Jogia J.R.
        • Caverzasi E.
        • et al.
        QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.
        Ann Gen Psychiatry. 2005; 4: 1-6
        • Thomas D.
        • Gut B.
        • Wendt-Nordahl G.
        • Kiehn J.
        The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels.
        J Pharmacol Exp Ther. 2002; 300: 543-548
        • Tarantino P.
        • Appleton N.
        • Lansdell K.
        Effect of trazodone on hERG channel current and QT-interval.
        Eur J Pharmacol. 2005; 510: 75-85
        • Winkler D.
        • Ortner R.
        • Pirek E.
        • Aschauer H.
        • Kasper S.
        Trazodone-induced cardiac arrhythmias: a report of two cases.
        Hum Psychopharmacol. 2006; 21: 61-62
        • Burgess C.D.
        • Hames T.K.
        • George C.F.
        The electrocardiographic and anticholinergic effects of trazodone and imipramine in man.
        Eur J Clin Pharmacol. 1982; 23: 417-421
        • Rajamani S.
        • Eckhardt L.L.
        • Valdivia C.R.
        • Klemens C.A.
        • Gillman B.M.
        • Anderson C.L.
        • et al.
        Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
        Br J Pharmacol. 2006; 149: 481-489
        • Pacher P.
        • Kecskemeti V.
        Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?.
        Curr Pharm Des. 2004; 10: 2463-2475
        • Park K.S.
        • Kong I.D.
        • Park K.C.
        • Lee J.W.
        Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes.
        Yonsei Med J. 1999; 40: 144-151
        • Roden D.M.
        • Viswanathan P.C.
        Genetics of acquired long QT syndrome.
        J Clin Invest. 2005; 115: 2025-2032
        • Drew B.J.
        • Califf R.M.
        • Funk M.
        • Kaufman E.S.
        • Krucoff M.W.
        • Laks M.M.
        • et al.
        Practice standards for electrocardiographic monitoring in hospital settings.
        Circulation. 2004; 110: 2721-2746
        • Drew B.
        • Funk M.
        Practice standards for ECG monitoring in hospital settings: executive summary and guide for implementation.
        Crit Care Nurs Clin N Am. 2006; 18: 157-168
        • Drew B.J.
        Pulling it all together.
        AACN Adv Crit Care. 2007; 18: 305-317
        • Viskin S.
        Long QT syndromes and torsades de pointes.
        Lancet. 1999; 354: 1625-1633
        • Vincent G.M.
        Prevention of drug-induced long QT syndrome: gender, chemistry, and education.
        J Cardiovasc Electrophysiol. 2001; 12: 546-547